| Patient | Vivekananda |
|---|---|
| Date of birth | 1991-01-12 |
| Identifiers | MRN HR-NI032-SYN; SSN (made up) 000-32-9014 |
| Document date | 2026-10-20 |
| Author | Anjali Thornbury-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Attacks of breathlessness and wheeze, the worst last night, two days after returning from the mountains. [S]
Swami Vivekananda returned two days ago from seven months of travel in the mountains. He was well in the dry, cool hills. For about three weeks, since coming down to the damp plains, he has had attacks of wheeze, cough and tightness lasting hours, mostly at night, and last night he sat up for most of the night feeling that he was suffocating. Smoke from the kitchen fires and incense make it worse. He has never had asthma diagnosed and has no inhaler. He has no fever, chest pain, ankle swelling or orthopnea between attacks, and no green sputum. He has taken metformin 2000 mg, losartan and atorvastatin throughout his travels; his fasting readings were 110 to 135 mg/dL, and 196 mg/dL this morning after a sleepless night. [S]
| Element | Detail |
|---|---|
| Onset | Three weeks, since coming down to the plains; worst last night |
| Severity | Sat up most of the night; speaks in sentences today; peak flow 330 L/min |
| Context | Type 2 diabetes on metformin; no previous asthma diagnosis or inhaler |
| Associated signs and symptoms | Night cough; no fever, chest pain, edema or purulent sputum |
| Glucose | Fasting 110 to 135 mg/dL while travelling; 196 mg/dL this morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Exhausted after a sleepless night; no fever |
| Respiratory | Positive | Wheeze, cough, chest tightness and breathlessness at night |
| Cardiovascular | Negative | No chest pain, palpitations at rest, orthopnea between attacks or ankle swelling |
| Ears, nose, mouth, and throat | Negative | No cold or sore throat |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week | 1000 mg with the evening meal | Oral route | 2026-02-16 to 2026-03-23 | completed | S |
| Metformin extended-release 500 mg tablets: four tablets (2000 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink | 2000 mg with the evening meal | Oral route | 2026-03-23 | active | S |
| Losartan 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Atorvastatin 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) each morning for five days | 40 mg each morning for five days | Oral route | 2026-10-20 to 2026-10-24 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer, one inhalation as needed for wheeze or breathlessness, no more than 12 inhalations a day, until lung function testing | One inhalation as needed | Respiratory tract route | 2026-10-20 to 2026-10-27 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-20 | Body height | 172 | cm | S |
| 2026-10-20 | Body weight | 74.6 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 108 | /min | S |
| 2026-10-20 | Respiratory rate | 24 | /min | S |
| 2026-10-20 | Body temperature | 36.9 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-20 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 330 | L/min | 80 percent of his predicted 590 L/min | Low | S |
Vital signs recorded on 2026-10-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired, sitting upright, speaking in full sentences; mild use of the neck muscles |
| Vital signs | Pulse 108, respiratory rate 24, oxygen saturation 94 percent on room air, temperature 36.9 °C; peak flow 330 L/min (56 percent of predicted) |
| Respiratory | Widespread expiratory wheeze with fair air entry; no crackles |
| Cardiovascular | Tachycardic, regular; jugular venous pressure not raised; no edema |
| Reassessment after one hour | After albuterol 4 puffs by spacer three times over an hour: peak flow 410 L/min (69 percent, a rise of 24 percent), oxygen saturation 96 percent, pulse 98, wheeze much reduced |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptide | resolved | confirmed | R73.9 | S — Synthetic presenting problem anchored to his documented diabetes of the year before. Superseded by the diagnosis at the second visit. |
| Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetes | active | confirmed | E11.65 | S — Synthetic modern confirmation and classification linked to his documented diabetes. |
| Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six months | active | confirmed | R80.9 | S — Synthetic finding linked to his documented albuminuria; superseded when diabetic kidney disease was confirmed. |
| Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be taken | resolved | confirmed | R03.0 | S — Synthetic finding; not a claim about his real blood pressure. |
| Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetes | active | confirmed | I10 | S — Synthetic finding of the modern episode; not a claim about his real blood pressure, which was never recorded. |
| Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditation | active | confirmed | G47.00 | S — Synthetic modern problem linked to his documented lifelong difficulty falling asleep. |
| Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36 | active | confirmed | E78.2 | S — Synthetic cardiovascular risk factor. |
| Attacks of wheeze and breathlessness for three weeks since coming down from the mountains to the damp plains, the worst last night with a sense of suffocation: peak flow 330 L/min (56 percent of predicted), oxygen saturation 94 percent, rising to 410 L/min after bronchodilator; no fever, edema or chest pain; chest X-ray and ECG without heart failure or pneumonia. Asthma to be confirmed with spirometry | active | confirmed | R06.2 | S — Synthetic presenting problem anchored to his documented suffocating attacks of asthma on his return to Belur. Superseded by the diagnosis a week later. |
Guideline basis: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020)
Follow-up: Review in one week with spirometry and FeNO; telephone call from the nurse in two days about breathing and glucose. Next scheduled visit 2026-10-27: review after seven months away and a week after an asthma attack: A1c, kidneys, lipids, spirometry with bronchodilator response and FeNO; asthma and diabetic kidney disease confirmed; empagliflozin and maintenance-and-reliever inhaler; fasting plan for the coming festival. [S]